Abstract
Opinions differ on the effectiveness and the risk involved in treating depressive illnesses with combinations of monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants. Some authorities, including the Food and Drug Administration in the United States, the former Witts Committee in this country, and the pharmaceutical firms producing antidepressants, have given serious warnings against combining MAOIs with tricyclic antidepressants. These warnings have been repeated more recently by Beck (1967), Malitz (1966) and Shepherd et al. (1968).
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Reference53 articles.
1. ‘Imiprainme-tranylcyproinine incompatibility.’;Brachfeld;Journal of American Medical Association,1963
2. NON-FATAL REACTION TO IMIPRAMINE-MAO INHIBITOR COMBINATION
3. TRANSIENT BRAIN SYNDROME AS A NON-FATAL REACTION TO COMBINED PARGYLINE IMIPRAMINE TREATMENT
4. ‘New treatment of some chronic tension states.’;Sargant;British Medical Journal,1966
Cited by
73 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献